Status:
UNKNOWN
USE THE SYSTEMIC METFORMIN IN MELASMA
Lead Sponsor:
Assiut University
Conditions:
Melasma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Melasma is a chronic and relapsing acquired dyschromia due to an increased epidermal-melanin unit activity that affects sun-exposed areas mainly in women throughout the reproductive years. It is more ...
Detailed Description
Its pathogenesis is not fully understood, nevertheless there is evidence that melanogenesis in melasma differ from tanning and post-inflammatory hyperpigmentations as well as there is an involvement o...
Eligibility Criteria
Inclusion
- All patients above 18 years old with melasma.
- With Fitzpatrick skin phototypes ranging from Type III-V will recruited.
Exclusion
- Pregnant or nursing women.
- Current use of hormonal birth control medication or any hormonal therapy, Use of topical hydroquinone within 3 months of study, Use of topical steroids within 1 month of study, Regular use of tanning parlors and History of laser or dermabrasion to the face within 9 months of study.
- Occupation involving primarily outdoor activities.
- History of kidney dysfunction diabetic (excluded by history and laboratory), Significant cardiovascular or respiratory disease and any other systemic diseases(i.e,history of endocrine disorders).
- patients with poor wound healing, recurrent herpes labialis and current skin infection (facial warts, molluscum contagiosum, history of hypertrophic scar/keloids, active dermatosis of atopic, seborrheic or other eczematous type).
- Photosensitivity,
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03475524
Start Date
April 1 2019
End Date
August 1 2021
Last Update
August 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assuit University
Asyut, Egypt, 71111